Global partnerships for biosimilar commercialization announced / Pharma News / Home - GaBi Online

Global partnerships for biosimilar commercialization announced

Home/Pharma News | Posted 14/08/2025 0 Post your comment

The biosimilar market is expanding rapidly, with key partnerships announced in mid-2025. Alvotech–Dr Reddy’s, Samsung Bioepis–NIPRO, and Formycon’s collaborations with Bio Usawa and Valorum Biologics aim to commercialize biosimilars for pembrolizumab, ustekinumab, ranibizumab, and aflibercept, targeting global markets ahead of patent expirations.

In June and July 2025, partnerships were announced between Alvotech and Dr Reddy’s Laboratories to produce and market a biosimilar candidate referencing Keytruda (pembrolizumab), as well as between Samsung Bioepis and NIPRO for multiple biosimilar candidates in Japan. Additionally, Formycon announced collaborations with African biotechnology company Bio Usawa Biotechnology and US-based Valorum Biologics to commercialize its ranibizumab and aflibercept biosimilars.

Anticipating Merck’s Keytruda (pembrolizumab) losing market exclusivity in 2028, Alvotech and Dr Reddy’s have partnered to co-develop, manufacture, and commercialize a biosimilar candidate referencing theproduct.

South Korea’s Samsung Bioepis and Japan’s NIPRO have entered into a license, development, and commercialization agreement for multiple biosimilar candidates, including Samsung Bioepis’ SB17 (an ustekinumab biosimilar candidate), in Japan. Samsung Bioepis will handle development, manufacturing, and supply, while NIPRO will oversee commercialization in Japan.

Bioeq, the exclusive global licensee of Formycon’s FYB201 (a ranibizumab biosimilar candidate), has partnered with Bio Usawa Biotechnology under an exclusive agreement. This grants Bio Usawa the rights to register and commercialize FYB201 under the brand name BioUcenta in Africa.

Additionally, Klinge Biopharma–the exclusive global rights holder for Formycon’s FYB203/Ahzantive (anaflibercept biosimilar)–has entered into a license agreement with Valorum Biologics for commercialization in the US and Canada.

Samsung Biologics to spin-off Samsung Bioepis

Tocilizumab and pembrolizumab biosimilar advances for Korean firms

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: El ‘One Big Beautiful Bill’ de Trump: implicaciones para la sanidad estadounidense

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: El ‘One Big Beautiful Bill’ de Trump: implicaciones para la sanidad estadounidense

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.